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Type 2 diabetes mellitus
rs11196205
rs3792267Background: Type 2 diabetes mellitus is a multifactorial and heterogenic disease with a complex etiology.
In recent decades the association of a large number of genes has been shown with T2DM. CAPN10 gene
was the first T2DM candidate gene identified through genome-wide screening and positional cloning, and
among all identified genes until now, TCF7L2 gene has shown most association with T2DM. The aim of
this study was to investigate the association between TCF7L2 rs11196205(C/G) and CAPN10 rs3792267
(G/A) with T2DM in a subset of Iranian population from Khuzestan province. It should be noted that this
is the first report of TCF7L2 polymorphism rs11196205with T2DM in Iran.
Subjects and methods: A case-control association study was performed using 150 T2DM patients and 150
controls. Genotyping for TCF7L2 rs11196205 was done by Tetra-Primer ARMS-PCR and for CAPN10
rs3792267 was done by PCR-RFLP Technique.
Results: Statistical analyses were carried out using SPSS version 16. In examining TCF7L2 rs11196205
based on the genotype GG, results for CG genotype were, 95%CI = (0.5–1.7), OR = 0.92, P-value = 0.79
and for genotype CC were, 95%CI = (0.94–3.92), OR = 1.92, P-value = 0.07. in examining CAPN10
rs3792267 based on the genotype AA, results for GG genotype were, 95%CI = (0.55–6.8), OR = 1.93,
P-value = 0.31 and for genotype GA were, 95%CI = (0.43–5.64), OR = 1.55, P-value = 0.5. So, in both
polymorphisms, none of the alleles or genotypes had significant statistical differences between case
and control groups (P > 0.05).
Conclusion: Our results showed that TCF7L2 rs11196205 and CAPN10 rs3792267 (SNP- 43) polymor-
phisms are not associated with the risk of T2DM in the studied population.
 2018 Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
One of the most common form of diabetes, constituting 95% of
the diabetic population is Type 2 diabetes mellitus. It is a heteroge-
neous group of disorders which is associated by hyperglycemia that
can occur through mechanisms such as impaired insulin secretion,
insulin resistance in peripheral tissues and increased glucoseoutput by the liver [1,2]. Genetic and environmental factors have
a strong role in themanifestation of T2DM as a complex genetic dis-
order. It is becoming an epidemic with increasing prevalence
throughout the world [3]. As reported, the prevalence of diabetes
has been estimated about 400 million people in the world while
>150 million of them seem to be still undiagnosed. It is predicted
that this prevalence by 2035 reaches to around 600 million [4]. In
Iran, the prevalence of T2DMwas about 24% as showed by a system-
atic review between years 1996 and 2004, and the risk was 1.7%
greater for women than for men. According to this report the preva-
lence of T2DM in Iran seems to be highest amongst developing
countries. Previous reports on total urban population ofMiddle East
countries show the prevalence of T2DM as 3.4% in Sudan, 20% in
UnitedArab Emirates, 8.5% in Bahrain, and 12.1% in India [5]. Chang-
ing patterns of diet, as well as decrease in physical activity practice
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T2DM prevalence observed over the past decades. However, it is
suggested but only in the presence of genetic risk factors, these life-
style changes may lead to T2DM [6]. Great effort has been made to
identify the genes which are associated with T2DM, and so far, sev-
eral novel susceptibility genes have been uncovered across several
ethnic groups, Using GWAS and candidate gene approaches [7,8].
Common variants in TCF7L2 (transcription factor 7-like 2) gene
have been identified as the strongest genetic risk factors for T2DM
in multiple ethnic groups [9]. Initially, strong association of TCF7L2
with T2DM was reported in Icelandic people and then subsequent
replication has been found in U.S and Danish populations [3].
TCF7L2 gene which spans about 215.9 Kb with 17 exons is located
on chromosome 10q25.3. This gene encodes a transcription factor
which is involved in the wnt signaling pathway. TCF7L2 gene which
affects insulin secretion and glucose production, is expressed in
many tissues including fat, liver and pancreatic islets of Langer-
hans. It has been shown that TCF7L2 gene plays a central role in
coordinating the expression of proinsulin and its subsequent pro-
cessing to form mature insulin [10,11]. rs11196205 at the TCF7L2
gene is located in intron 4 [12].
Among the >40 genes related to T2DM (OMIM, 2013), the asso-
ciation of CAPN10 (calpain-10) gene was initially reported with
diabetes in Mexican-Americans people [13]. Association of CAPN10
gene polymorphisms in development of T2DM in multiple ethnic
groups in several case-control studies has been indicated. CAPN10
gene is located on chromosome 2q37.3, and with 15 exons span-
ning 31 kb, which encodes a 672 amino-acid intracellular protease
[14]. Similar to other calpains, CAPN10 consists of an isoform-
specific large subunit and a common small subunit, and was shown
to act as intracellular calcium-dependent cysteine proteases in
calcium-regulated signaling pathways [15]. Although CAPN10 is
highly expressed in heart, brain, liver, kidney and pancreas, its
main role is in tissues such as skeletal muscle. Howbeit insulin
secretion, insulin action, insulin stimulated glucose transport and
insulin stimulated glycogen synthesis are the significant metabolic
activities related to the disease of an individual, evidences from the
studies show that there are susceptibility genes controlling these
metabolic activities and CAPN10 and its variants contribute to the
metabolic activities and T2DM [16]. rs3792267(G/A) at the CAPN10
gene is located in the third intron [14].
The aim of this study was investigation of association between
rs11196205(C/G) at TCF7L2 gene and rs3792267(G/A) at CAPN10
with T2DM in a population from Khuzestan province, Iran.
2. Subjects and methods
2.1. Subjects
The type of study was case-control and a total of 300 individu-
als, including 150 unrelated adult T2DM patients (77 men and 73Table 1






Mean Age (years) 52.51 ± 9.15
Diabetes duration (years) 6.32 ± 3.97
Mean B.M.I (kg/m2) 28.9 ± 5.02
FPG (mg/dl) 172.15 ± 81.
HBA1c(%) 8.31 ± 2.33
TG (mg/dl) 144.76 ± 55.
TC (mg/dl) 177.9 ± 48.5women; age 52.51 ± 9.15 years) who were selected from among
those referred to the Diabetes Clinic and Golestan Hospital in
Ahvaz, and 150 unrelated controls (71 men and 79 women; age
56.49 ± 7.18 years) who were selected from among people referred
to Valiasr Hospital in Khoramshahr and Golestan Hospital of Ahvaz
(Table 1). T2DM criteria were based on the standard of ADA.
According to which FPG  126 mg/dl or 2-hPG (2h Plasma Glu
cose)  200 mg/dl or RBG (Random Blood Sugar)  200 mg/dl to
be characterized as diabetic. People with diabetes were chosen as
samples that were taking medicines to treat diabetes. For control
individuals, lack of history of diabetes in the subjects and among
their first-degree relatives was carefully monitored. The case and
control subjects were living in Khuzestan province. The project
has been approved by especial committee genetic division of Sha-
hid Chamran university for considering the ethical issues of
patients and controls who participated in sampling. Before blood
sampling, both diabetic patients and healthy subjects signed the
consent form to participate in this study. The present study has
been carried out in accordance with the Code of Ethics of the world
Medical Association (Declaration of Helsinki) for experiments in
humans.
2.2. DNA extraction and genotyping
Leukocyte Genomic DNA was extracted from whole blood sam-
ples by non-enzymatic salting out method. All participants were
genotyped for two SNPs including TCF7L2 rs11196205 (C/G) and
CAPN10 rs3792267 (G/A).
2.2.1. TCF7L2 rs11196205
Genotyping for rs11196205 was carried out using the TETRA
ARMS PCR technique and following primers were used: forward
inner primer: 50-CTGAAAGTTCTCAACATTTATAACTGCC-30 and
reverse inner primer: 50-CAACCATAACTCTCTTACATACTGGTC-30
and forward outer primer: 50-TAGATTGTCTCCTTTTGTTTCTGCTAC-30
and reverse outer primer: 50-TAAACATCTGACCTTGA AGCCTACC-30.
Master Mix PCR was provided from Ampliqon Company. Using
Bio-Rad thermal cycler, each PCR was performed in a volume of
25 ll, including 2 ll of genomic DNA, 0.75 ll of each external pri-
mer, 2 ll of each internal primer, 5 ll of distilled water, and 12.5 ll
of Master mix. The size of DNA fragments amplified with these four
primers for TCF7L2 (434 bp control fragment, 253 bp C allele,
235 bp G allele), was suitable for separation on 3% agarose gel.
To determine the size of DNA fragment in gel the 50 bp Ladder
was used.
2.2.2. CAPN10 rs3792267
rs3792267 was genotyped using PCR-RFLP Technique. For this
purpose, the part of CAPN10 gene that contains intended polymor-
phism, was amplified by PCR technique using the primer pair
50-CACGCTTGCTGTGAAGTAATGC-30 (forward) and 50-TGATTCCControls P-value
71(47.3%) P > 0.05
79(52.7%) P > 0.05
96(%64) P > 0.05
54(%36) P > 0.05
56.49 ± 7.18 P < 0.01
– –
26.49 ± 4.52 P < 0.001
4 91.37 ± 6.29 P < 0.001
– –
63 122.81 ± 56.96 P < 0.001
4 184.21 ± 53.18 P > 0.05
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formed using the following reagents: 1.5 ll of genomic DNA,
0.75 ll of each primer, 9.5 ll of distilled water, and 12.5 ll of Mas-
ter Mix. PCR amplification of CAPN10 gene produced a 141 bp DNA
fragment. In order to confirm the PCR amplification, gel elec-
trophoresis (1/5% agarose gel and DNA safe stain) was done. For
RFLP analysis 8 ll of PCR product was digested by 4U of a restric-
tion enzyme Mph1103I (Fermentas) at 37 C for 16 h in 20 ll reac-
tion mixture that contained 10x Buffer R.
The G-allele was not cleaved by Mph1103I and gave a 141 bp
band and the A-allele was cleaved into two bands 118 and 23 bp.
It should be noted that the 23 bp fragment cannot be seen due to
its small size in the gel. The digested products were separated by
running on 2/5% agarose gel with DNA size marker of 50 bp and
observed using a UV transilluminator.2.3. Statistical analysis
All statistical analyses were performed using SPSS v.16.0 soft-
ware. Data for continuous variables were expressed as mean ± stan
dard deviation (SD). The differences in continuous data between
T2DM patients and control participants were assessed using
Mann-Whitney test. Categorical data such as allele and genotype
frequencies are shown as number (percentage) and analyzed by
x2 test. For evaluating of association of TCF7L2 rs11196205 and
CAPN10 rs3792267 polymorphisms with T2DM, Odds Ratios
(ORs), 95% confidence intervals (95% CIs) and corresponding P val-
ues were calculated using logistic regression. P < 0.05 was consid-
ered statistically significant.
Variables with normal distribution are presented as mean ± SD
or percentage, p values <0.05 are considered as significant. BMI:
body mass index, FPG: fasting plasma glucose, HbA1c: hemoglobi-
nA1c, TG: triglyceride, TC: total cholesterol.Fig. 1. Agarose gel electrophoresis (3%) of PCR product of Tetra-Primer ARMS-PCR
for TCF7L2 rs11196205.3. Results
The clinical and biochemical characteristics of the participants
are summarized in Table 1. Our results showed statistically signif-
icant differences for diabetes criteria between control and T2DM
patients (P < 0.001). The average age of control group was signifi-
cantly higher than the average age of patients (P < 0.01), and the
mean of BMI and triglycerides were significantly higher in patient
group than the control group (P < 0.001), but there were no statis-
tically significant differences between control and T2DM patients
for sex, ethnicity (Arab and non-Arab) and total cholesterol (P > 0
.05). The results of PCR product of TETRA ARMS-PCR for TCF7L2
rs11196205 and PCR amplification of CAPN10 gene and digestion
results of PCR products are shown in Figs. 1–3.
To determine the association of TCF7L2 rs11196205 and CAPN10
rs3792267 polymorphisms with T2DM, we analyzed the distribu-
tion of allelic and genotypic frequencies between patients and
healthy controls for both SNPs and our results revealed that there
was no statistically significant differences for allele and genotype
frequencies of TCF7L2 rs11196205 or CAPN10 rs3792267 polymor-
phisms between subjects with T2DM and non-diabetic subjects.
The allele and genotype frequencies of TCF7L2 rs11196205(C/G)
are shown in Tables 2 and 3. The prevalence of genotypeFig. 2. Electrophoresis of PCR Product 141 bp for the amplification of the CAPN10
rs3792267 on 1.5% agarose gel.
Fig. 3. 2.5% agarose gel showing results for CAPN10 rs3792267 in some individuals;
GG homozygote is observed as a fragment of 141 bp and AA homozygote is
observed as a fragment of 118 bp and heterozygote (GA) is observed as two
fragments (141 and 118 bp).
Table 2





Genotype frequency of TCF7L2 rs11196205 in the cases and controls.
Genotype Controls Cases
Total (N%) Female (N%) Male (N%) Total (N%) Female (N%) Male (N%)
CC 28(18.66%) 12(8%) 16(10.66%) 48(32%) 25(16.66%) 23(15.33%)
CG 94(62.66%) 56(37.33%) 38(25.33%) 77(51.33%) 35(23.33%) 42(28%)
GG 28(18.66%) 11(7.33%) 17(11.33%) 25(16.66%) 13(8.66%) 12(8%)
Table 4
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(51.33%) and 25(16.66%) in diabetic and 28(18.66%), 94(62.66%)
and 28(18.66%) in control groups. By general comparison between
genotypic frequencies of cases and controls, a significant difference
was seen (X2 = 7.12, df = 2, P-value = 0.028). But in the logistic
regression analysis, considering GG genotype as a basis, the follow-
ing results were obtained for genotype CG: OR = 0.92, 95%CI = (0.5–
1.7), P-value = 0.79 and for genotype CC the following results were
obtained: OR = 1.92, 95%CI = (0.94–3.92), P-value = 0.07. the fre-
quencies of C and G alleles in patients with diabetes were 57.66%
and 42.33%, respectively, and in the healthy subjects was 50% for
each of the alleles (95%CI = 0.99–1.88, OR = 1.36, P-value = 0.06).
So, there was no very significant difference between the two
groups. The allele and genotype frequencies of CAPN10
rs3792267(G/A) are shown in Tables 4 and 5. According to the find-
ings of Table 5, CAPN10 rs3792267 genotype frequencies were 60%,
35.33%, and 4.66% in control group and 66%, 31.33%, and 2.66% in
T2DM patients for GG, GA, and AA, respectively. In a general com-
parison between genotypic frequencies of cases and controls, the
difference was not significant (X2 = 1.61, df = 2, P-value = 0.45).
Also in the logistic regression analysis, considering AA genotype
as a basis, the following results were obtained for genotype GG:
OR = 1.93, 95% CI = (0.55–6.8), P-value = 0.31 and for genotype
GA: OR = 1.55, 95%CI= (0.43–5.64), P-value = 0.5. The prevalence
of G and A allele frequencies in diabetic subjects, were respectively
81.66% and 18.33% and in the controls were 77.66% and 22.33% (
95%CI = 0.86–1.91, OR = 1.28, P-value = 0.2). These results don’t
show significant difference between the two groups.
4. Discussion
In the present study, we examined the association of TCF7L2
rs11196205 and CAPN10 rs3792267 polymorphisms with T2DM
in Khuzestan Province, Iran using a case-control method. TCF7L2
gene plays a key role in the homeostasis of glucose and beta cell
function [3]. The association of TCF7L2 variants with T2DM has
been reported by many studies in different populations [17]. How-
ever, some studies have reported weak or no association with this
disease, mainly in Asian populations [18–20]. In all GWAS that has
been done, TCF7L2 gene clearly showed the largest effect size withTable 5
Genotype frequency of CAPN10 rs3792267 in the cases and controls.
CGenotype Controls
Total (N%) Female (N %) Male (N
GG 90(60%) 55(36.66%) 35(23.3
GA 53(35.33%) 20(13.33%) 33(22%
AA 7(4.66%) 4(2.66%) 3(2%)an odds ratio of 1.37 and according to meta-analyses that were
conducted by Florez and also Cauchi et al., the TCF7L2 gene is a
strong susceptibility gene for T2DM in different ethnic groups
[17,21,22]. In our study on TCF7L2 rs11196205(C/G) polymor-
phism, the frequency of CC genotype in patient group was higher
than healthy group, while frequency of CG and GG genotype in
healthy subjects was higher than the patient group. Also, frequency
of C allele was higher in the patient group. But in general, contrary
to the results of many studies conducted in other populations,
TCF7L2 rs11196205 did not show significant association with
T2DM in population of Khuzestan province. This is the first report
of association study of TCF7L2 rs11196205 polymorphism with
T2DM in Iran. Doing a cross-national research with larger sample
sizes would help us to achieve a more accurate result.
CAPN10 was the first T2DM candidate gene identified through
genome-wide screening and positional cloning [23,24]. Specific
CAPN10 variants, such as rs3792267 reportedly confers increased
risk of T2DM in some populations [25–31]. But the association of
CAPN10 rs3792267 with T2DM in some other studies has not con-
firmed [14,32–36].So far, two studies have been conducted on the
association of rs3792267 with T2DM in Iran; a study in 2012 by
Bahraini and colleagues was conducted on the population of West
Azerbaijan, and G allele as a risk factor for T2DM in this population
was identified. In another study by Maleki and his colleagues on
the Kurdish ethnicity in Ilam city in 2014, the association between
rs3792267 and T2DM was not confirmed [37,38]. This is the first
study performed on the association of CAPN10 rs3792267 with
T2DM in the population of Khuzestan province from southwest
Iran. In this study, CAPN10 rs3792267 did not show either allelic
or genotypic association with T2DM.5. Conclusion
The study of the role of genetic factors in development of
heterogeneous multifactorial diseases, such as T2DM, is very com-
plicated, because the genetic analysis of this disease, in addition to
identifying and estimating the contribution of different variants in
different genes that are effective, requires to understand the inter-
actions between these genes and variants as well as their cumula-
tive effects. our results suggested that TCF7L2 rs11196205 and
CAPN10 rs3792267 polymorphisms are not associated with the
risk of T2DM in Khuzestan province, Iran. The difference and diver-
sity in results of mentioned studies and the present study may be
influenced by many factors such as ethnic differences (the role and
effect of genetic varieties in different ethnic groups), environmen-
tal factors and epigenetic effects, sample size, diagnostic method,Cases
%) Total (N%) Female (N) Male (N%)
3%) 99(66%) 54(36%) 45(30%)
) 47(31.33%) 18(12%) 29(19.33%)
4(2.66%) 1(0.66%) 3(2%)
A. Gravand et al. / The Egyptian Journal of Medical Human Genetics 19 (2018) 403–407 407differences in sampling methods (in terms of demographic charac-
teristics such as age and sex) and other factors.
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